Ruchan Karaman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruchan Karaman has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Georg Halder
Department of Oncology, KU Leuven, Leuven, Belgium; VIB Center for Cancer Biology, KU Leuven, Leuven, Belgium
3 shared publications - Carmen Menacho
VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
2 shared publications - Dietmar Schmucker
VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany; Leuven Brain Institute, Herestraat 49, Leuven 3000, Belgium
2 shared publications Filip de Vin
VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium
2 shared publications- Frank Schnütgen
Goethe University Frankfurt, Department of Medicine, Hematology/Oncology, Frankfurt/Main, Germany
2 shared publications - Gabriela Edwards-Faret
VIB Center for Brain and Disease Research, Herestraat 49, Leuven 3000, Belgium; KU Leuven Department of Neuroscience, Herestraat 49, Leuven 3000, Belgium; Neuronal Wiring Group, Life & Medical Sciences Institute, University of Bonn, Carl-Troll-Straße 31, Bonn D53115, Germany
2 shared publications
Latest Publications
- Open Access
Genomize-SEQ: An NGS data analysis platform for genomic variant classification and prioritization
Accurate interpretation of diverse genetic variants remains a pivotal challenge in the diagnosis of rare diseases. Although evidence-based guidelines established by the American College of Medical Genetics and Genomics have enhanced the precision of variant assessment, the practical implementation of this evidence-based classification can be challenging. The inherent genetic heterogeneity in rare diseases, coupled with the need to integrate information from numerous databases, contributes to this complexity. Therefore, advancements in secondary variant calling, automated variant annotation and prioritization, visualization of variant annotations with the raw data, and a streamlined reporting process are crucial for efficient and robust analysis. Here we present Genomize-SEQ, a web-based clinical genomics analysis software that has all of these capabilities, with which more than 300,000 patients have been analyzed to date. Genomize-SEQ collects data from more than 120 different databases to annotate the variants according to ACMG/AMP guidelines and prioritize the variants that could be causative for the clinical presentation of a patient. Genomize-SEQ can also perform real-time data aggregation to calculate variant frequencies in each center as well as the community. This capability helps clinicians to analyze variants more easily in regions without genome projects or in populations underrepresented in existing databases. We validated the annotation capacity of Genomize-SEQ by performing a systematic comparison of ACMG pathogenicity prediction from widely used algorithms and Genomize-SEQ’s algorithm, using ClinGen’s expert curation dataset as a truth set. In addition, we tested the prioritization efficiency of Genomize-SEQ by using real-world whole-exome sequencing data of 215 patients with pre-diagnostic and phenotypic information. Genomize-SEQ identified the causative variants with a 97% success rate, with 52% of these variants ranked in the top position and over 90% ranked within the top 20. Thus, Genomize-SEQ provides a complete solution for comprehensive variant interpretation to achieve fast and reliable diagnosis for rare diseases from next-generation sequencing data.
Open AccessGenomize-SEQ: An NGS data analysis platform for genomic variant classification and prioritization
Accurate interpretation of diverse genetic variants remains a pivotal challenge in the diagnosis of rare diseases. Although evidence-based guidelines established by the American College of Medical Genetics and Genomics have enhanced the precision of variant assessment, the practical implementation of this evidence-based classification can be challenging. The inherent genetic heterogeneity in rare diseases, coupled with the need to integrate information from numerous databases, contributes to this complexity. Therefore, advancements in secondary variant calling, automated variant annotation and prioritization, visualization of variant annotations with the raw data, and a streamlined reporting process are crucial for efficient and robust analysis. Here we present Genomize-SEQ, a web-based clinical genomics analysis software that has all of these capabilities, with which more than 300,000 patients have been analyzed to date. Genomize-SEQ collects data from more than 120 different databases to annotate the variants according to ACMG/AMP guidelines and prioritize the variants that could be causative for the clinical presentation of a patient. Genomize-SEQ can also perform real-time data aggregation to calculate variant frequencies in each center as well as the community. This capability helps clinicians to analyze variants more easily in regions without genome projects or in populations underrepresented in existing databases. We validated the annotation capacity of Genomize-SEQ by performing a systematic comparison of ACMG pathogenicity prediction from widely used algorithms and Genomize-SEQ’s algorithm, using ClinGen’s expert curation dataset as a truth set. In addition, we tested the prioritization efficiency of Genomize-SEQ by using real-world whole-exome sequencing data of 215 patients with pre-diagnostic and phenotypic information. Genomize-SEQ identified the causative variants with a 97% success rate, with 52% of these variants ranked in the top position and over 90% ranked within the top 20. Thus, Genomize-SEQ provides a complete solution for comprehensive variant interpretation to achieve fast and reliable diagnosis for rare diseases from next-generation sequencing data.
- Open Access
- 15 June 2023
- Published by Elsevier in Neuroscience
- Vol. 528, 140-141
Corrigendum to “A New Technical Approach for Cross-species Examination of Neuronal Wiring and Adult Neuron-glia Functions” [Neuroscience 508 (2023) 40–51]
- 15 June 2023
- Published by Elsevier in Neuroscience
- Vol. 528, 140-141
Open AccessCorrigendum to “A New Technical Approach for Cross-species Examination of Neuronal Wiring and Adult Neuron-glia Functions” [Neuroscience 508 (2023) 40–51]
- 22 November 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 366 (6468) , 1029-1034
Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice
Mixed signals at tumor margins: The Hippo signaling pathway has been implicated in tumor growth, sparking interest in the pathway as a potential therapeutic target. In a study of liver cancer in genetically manipulated mice, Moya et al. discovered that the role of this pathway in tumorigenesis is more complex than previously appreciated. They confirmed that activation of the Hippo pathway within tumor cells drives tumor growth; however, they also found that activation of the pathway in adjacent healthy cells has the opposite effect, suppressing tumor growth. Whether tumor cells survive or are eliminated thus appears to depend on competing signals produced by the tumor and surrounding tissue. Science , this issue p. 1029
- 22 November 2019
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 366 (6468) , 1029-1034
Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice
Mixed signals at tumor margins: The Hippo signaling pathway has been implicated in tumor growth, sparking interest in the pathway as a potential therapeutic target. In a study of liver cancer in genetically manipulated mice, Moya et al. discovered that the role of this pathway in tumorigenesis is more complex than previously appreciated. They confirmed that activation of the Hippo pathway within tumor cells drives tumor growth; however, they also found that activation of the pathway in adjacent healthy cells has the opposite effect, suppressing tumor growth. Whether tumor cells survive or are eliminated thus appears to depend on competing signals produced by the tumor and surrounding tissue. Science , this issue p. 1029
- Open Access
- 1 February 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (3) , 638
YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role
Primary liver cancer comprises a diverse group of liver tumors. The heterogeneity of these tumors is seen as one of the obstacles to finding an effective therapy. The Hippo pathway, with its downstream transcriptional co-activator Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), has a decisive role in the carcinogenesis of primary liver cancer. Therefore, we examined the expression pattern of YAP and TAZ in 141 patients with hepatocellular carcinoma keratin 19 positive (HCC K19+), hepatocellular carcinoma keratin 19 negative (HCC K19−), combined hepatocellular–cholangiocarcinoma carcinoma (cHCC-CCA), or cholangiocarcinoma (CCA). All cHCC-CCA and CCA patients showed high expression levels for YAP and TAZ, while only some patients of the HCC group were positive. Notably, we found that a histoscore of both markers is useful in the challenging diagnosis of cHCC-CCA. In addition, positivity for YAP and TAZ was observed in the hepatocellular and cholangiocellular components of cHCC-CCA, which suggests a single cell origin in cHCC-CCA. Within the K19− HCC group, our results demonstrate that the expression of YAP is a statistically significant predictor of poor prognosis when observed in the cytoplasm. Nuclear expression of TAZ is an even more specific and independent predictor of poor disease-free survival and overall survival of K19− HCC patients. Our results thus identify different levels of YAP/TAZ expression in various liver cancers that can be used for diagnostics.
- 1 February 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (3) , 638
Open AccessYAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role
Primary liver cancer comprises a diverse group of liver tumors. The heterogeneity of these tumors is seen as one of the obstacles to finding an effective therapy. The Hippo pathway, with its downstream transcriptional co-activator Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), has a decisive role in the carcinogenesis of primary liver cancer. Therefore, we examined the expression pattern of YAP and TAZ in 141 patients with hepatocellular carcinoma keratin 19 positive (HCC K19+), hepatocellular carcinoma keratin 19 negative (HCC K19−), combined hepatocellular–cholangiocarcinoma carcinoma (cHCC-CCA), or cholangiocarcinoma (CCA). All cHCC-CCA and CCA patients showed high expression levels for YAP and TAZ, while only some patients of the HCC group were positive. Notably, we found that a histoscore of both markers is useful in the challenging diagnosis of cHCC-CCA. In addition, positivity for YAP and TAZ was observed in the hepatocellular and cholangiocellular components of cHCC-CCA, which suggests a single cell origin in cHCC-CCA. Within the K19− HCC group, our results demonstrate that the expression of YAP is a statistically significant predictor of poor prognosis when observed in the cytoplasm. Nuclear expression of TAZ is an even more specific and independent predictor of poor disease-free survival and overall survival of K19− HCC patients. Our results thus identify different levels of YAP/TAZ expression in various liver cancers that can be used for diagnostics.
- Open Access
- 9 June 2017
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 10 (5) , a028753
Cell Junctions in Hippo Signaling
The Hippo signal transduction pathway is an important regulator of organ growth and cell differentiation, and its deregulation contributes to the development of cancer. The activity of the Hippo pathway is strongly dependent on cell junctions, cellular architecture, and the mechanical properties of the microenvironment. In this review, we discuss recent advances in our understanding of how cell junctions transduce signals from the microenvironment and control the activity of the Hippo pathway. We also discuss how these mechanisms may control organ growth during development and regeneration, and how defects in them deregulate Hippo signaling in cancer cells.
- 9 June 2017
- Published by Cold Spring Harbor Laboratory in Cold Spring Harbor Perspectives in Biology
- Vol. 10 (5) , a028753
Open AccessCell Junctions in Hippo Signaling
The Hippo signal transduction pathway is an important regulator of organ growth and cell differentiation, and its deregulation contributes to the development of cancer. The activity of the Hippo pathway is strongly dependent on cell junctions, cellular architecture, and the mechanical properties of the microenvironment. In this review, we discuss recent advances in our understanding of how cell junctions transduce signals from the microenvironment and control the activity of the Hippo pathway. We also discuss how these mechanisms may control organ growth during development and regeneration, and how defects in them deregulate Hippo signaling in cancer cells.
- Open Access
- 1 October 2012
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 122 (11) , 4130-4144
Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis
A genetic variant in PNPLA3 (PNPLA3I148M), a triacylglycerol (TAG) hydrolase, is a major risk factor for nonalcoholic fatty liver disease (NAFLD); however, the mechanism underlying this association is not known. To develop an animal model of PNPLA3-induced fatty liver disease, we generated transgenic mice that overexpress similar amounts of wild-type PNPLA3 (PNPLA3WT) or mutant PNPLA3 (PNPLA3I148M) either in liver or adipose tissue. Overexpression of the transgenes in adipose tissue did not affect liver fat content. Expression of PNPLA3I148M, but not PNPLA3WT, in liver recapitulated the fatty liver phenotype as well as other metabolic features associated with this allele in humans. Metabolic studies provided evidence for 3 distinct alterations in hepatic TAG metabolism in PNPLA3I148M transgenic mice: increased formation of fatty acids and TAG, impaired hydrolysis of TAG, and relative depletion of TAG long-chain polyunsaturated fatty acids. These findings suggest that PNPLA3 plays a role in remodeling TAG in lipid droplets, as they accumulate in response to food intake, and that the increase in hepatic TAG levels associated with the I148M substitution results from multiple changes in hepatic TAG metabolism. The development of an animal model that recapitulates the metabolic phenotype of the allele in humans provides a new platform in which to elucidate the role of PNLPA3I148M in NAFLD.
- 1 October 2012
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 122 (11) , 4130-4144
Open AccessChronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis
A genetic variant in PNPLA3 (PNPLA3I148M), a triacylglycerol (TAG) hydrolase, is a major risk factor for nonalcoholic fatty liver disease (NAFLD); however, the mechanism underlying this association is not known. To develop an animal model of PNPLA3-induced fatty liver disease, we generated transgenic mice that overexpress similar amounts of wild-type PNPLA3 (PNPLA3WT) or mutant PNPLA3 (PNPLA3I148M) either in liver or adipose tissue. Overexpression of the transgenes in adipose tissue did not affect liver fat content. Expression of PNPLA3I148M, but not PNPLA3WT, in liver recapitulated the fatty liver phenotype as well as other metabolic features associated with this allele in humans. Metabolic studies provided evidence for 3 distinct alterations in hepatic TAG metabolism in PNPLA3I148M transgenic mice: increased formation of fatty acids and TAG, impaired hydrolysis of TAG, and relative depletion of TAG long-chain polyunsaturated fatty acids. These findings suggest that PNPLA3 plays a role in remodeling TAG in lipid droplets, as they accumulate in response to food intake, and that the increase in hepatic TAG levels associated with the I148M substitution results from multiple changes in hepatic TAG metabolism. The development of an animal model that recapitulates the metabolic phenotype of the allele in humans provides a new platform in which to elucidate the role of PNLPA3I148M in NAFLD.
- Open Access
- 19 January 2012
- Published by American Society of Hematology in Blood
- Vol. 119 (3) , 736-744
Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development
Hematopoietic stem cells (HSCs) interact with osteoblastic, stromal, and vascular components of the BM hematopoietic microenvironment (HM) that are required for the maintenance of long-term self-renewal in vivo. Osteoblasts have been reported to be a critical cell type making up the HSC niche in vivo. Rac1 GTPase has been implicated in adhesion, spreading, and differentiation of osteoblast cell lines and is critical for HSC engraftment and retention. Recent data suggest a differential role of GTPases in endosteal/osteoblastic versus perivascular niche function. However, whether Rac signaling pathways are also necessary in the cell-extrinsic control of HSC function within the HM has not been examined. In the present study, genetic and inducible models of Rac deletion were used to demonstrate that Rac depletion causes impaired proliferation and induction of apoptosis in the OP9 cell line and in primary BM stromal cells. Deletion of Rac proteins caused reduced trabecular and cortical long bone growth in vivo. Surprisingly, HSC function and maintenance of hematopoiesis in vivo was preserved despite these substantial cell-extrinsic changes. These data have implications for therapeutic strategies to target Rac signaling in HSC mobilization and in the treatment of leukemia and provide clarification to our evolving concepts of HSC-HM interactions.
- 19 January 2012
- Published by American Society of Hematology in Blood
- Vol. 119 (3) , 736-744
Open AccessRac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development
Hematopoietic stem cells (HSCs) interact with osteoblastic, stromal, and vascular components of the BM hematopoietic microenvironment (HM) that are required for the maintenance of long-term self-renewal in vivo. Osteoblasts have been reported to be a critical cell type making up the HSC niche in vivo. Rac1 GTPase has been implicated in adhesion, spreading, and differentiation of osteoblast cell lines and is critical for HSC engraftment and retention. Recent data suggest a differential role of GTPases in endosteal/osteoblastic versus perivascular niche function. However, whether Rac signaling pathways are also necessary in the cell-extrinsic control of HSC function within the HM has not been examined. In the present study, genetic and inducible models of Rac deletion were used to demonstrate that Rac depletion causes impaired proliferation and induction of apoptosis in the OP9 cell line and in primary BM stromal cells. Deletion of Rac proteins caused reduced trabecular and cortical long bone growth in vivo. Surprisingly, HSC function and maintenance of hematopoiesis in vivo was preserved despite these substantial cell-extrinsic changes. These data have implications for therapeutic strategies to target Rac signaling in HSC mobilization and in the treatment of leukemia and provide clarification to our evolving concepts of HSC-HM interactions.